Compare BCBP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | AGEN |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 147.4M |
| IPO Year | 2005 | 1999 |
| Metric | BCBP | AGEN |
|---|---|---|
| Price | $10.29 | $4.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.00 | ★ $14.50 |
| AVG Volume (30 Days) | 91.1K | ★ 1.2M |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $85.26 | $107.63 |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | $39.42 | ★ $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $7.31 | $2.71 |
| 52 Week High | $10.50 | $7.34 |
| Indicator | BCBP | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 55.64 |
| Support Level | $7.49 | $4.09 |
| Resistance Level | N/A | $4.25 |
| Average True Range (ATR) | 0.28 | 0.29 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 75.56 | 50.43 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.